Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized Phase 2 Trial of ACP-196 and Pembrolizumab Immunotherapy Dual CHECKpoint Inhibition In Platinum Resistant Metastatic Urothelial Carcinoma (RAPID CHECK Study)

NCT02351739 is registered in ClinicalTrials.gov with Acerta Pharma BV as lead sponsor.

NCT NCT02351739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02351739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized Phase 2 Trial of ACP-196 and Pembrolizumab Immunotherapy Dual CHECKpoint Inhibition In Platinum Resistant Metastatic Urothelial Carcinoma (RAPID CHECK Study)
Lead sponsor
Acerta Pharma BV
Phase
Phase 2
Overall status
Completed
Start date
April 30, 2015
Completion date
April 30, 2018
Enrollment
78 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic urothelial carcinoma